Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2011, Article ID 439456, 19 pages
http://dx.doi.org/10.1155/2011/439456
Review Article

Recent Advances in the Pathobiology of Hodgkin's Lymphoma: Potential Impact on Diagnostic, Predictive, and Therapeutic Strategies

1Centre for Translational and Applied Genomics (CTAG), Department of Pathology, British Columbia Cancer Agency (BCCA), 600 West 10th Avenue, Vancouver, British Columbia, Canada V5Z 4E6
2Department of Pathology and Laboratory Medicine, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada V6T 2B5

Received 1 July 2010; Revised 4 October 2010; Accepted 12 November 2010

Academic Editor: Stefan Faderl

Copyright © 2011 Diponkar Banerjee. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. Hodgkin, “On some morbid appearances of the absorbent glands and spleen,” Medico-Chirurgical Transactions, vol. 17, pp. 68–114, 1832. View at Google Scholar
  2. T. Hodgkin and J. J. Lister, “Notice of some microscopic observations of the blood and animal tissue,” Philosophical Magazine, vol. 2, pp. 130–138, 1827. View at Google Scholar
  3. R. N. Poston, “A new look at the original cases of Hodgkin's disease,” Cancer Treatment Reviews, vol. 25, no. 3, pp. 151–155, 1999. View at Publisher · View at Google Scholar · View at Scopus
  4. P. J. Dawson, “The original illustrations of Hodgkin's disease,” Annals of Diagnostic Pathology, vol. 3, no. 6, pp. 386–393, 1999. View at Google Scholar · View at Scopus
  5. H. Jackson Jr. and F. Parker, “Hodgkin’s disease. II. Pathology,” New England Journal of Medicine, vol. 231, pp. 35–44, 1944. View at Google Scholar
  6. R. J. Lukes and J. J. Butler, “The pathology and nomenclature of Hodgkin's disease,” Cancer Research, vol. 26, no. 6, pp. 1063–1083, 1966. View at Google Scholar · View at Scopus
  7. R. J. Lukes, L. Craver, l. T. Hal, H. Rappaport, and P. Ruben, “Report of the nomenclature committee,” Cancer Research, vol. 26, article 1311, 1966. View at Google Scholar
  8. N. L. Harris, E. S. Jaffe, H. Stein et al., “A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group,” Blood, vol. 84, no. 5, pp. 1361–1392, 1994. View at Google Scholar · View at Scopus
  9. S. H. Swerdlow, E. Campo, N. L. Harris et al., WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon, France, 4th edition, 2008.
  10. Canadian Cancer Society's Steering Committee, “Canadian Cancer Statistics 2010,” Canadian Cancer Society, 2010.
  11. A. Diepstra, M. Niens, G. J. te Meerman, S. Poppema, and A. van den Berg, “Genetic susceptibility to Hodgkin's lymphoma associated with the human leukocyte antigen region,” European Journal of Haematology, Supplement, vol. 75, no. 66, pp. 34–41, 2005. View at Google Scholar · View at Scopus
  12. GLOBOCAN 2008, International Agency for Research on Cancer, 2008, http://globocan.iarc.fr/.
  13. M. A. Epstein and B. G. Achong, “Various forms of Epstein Barr virus infection in man: established facts and a general concept,” Lancet, vol. 2, no. 7833, pp. 836–839, 1973. View at Google Scholar · View at Scopus
  14. A. Punnett, R. W. Tsang, and D. C. Hodgson, “Hodgkin lymphoma across the age spectrum: epidemiology, therapy, and late effects,” Seminars in Radiation Oncology, vol. 20, no. 1, pp. 30–44, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. F. C. Eberle, H. Mani, and E. S. Jaffe, “Histopathology of Hodgkin's lymphoma,” Cancer Journal, vol. 15, no. 2, pp. 129–137, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. M. J. R. L. Horner, M. Krapcho, N. Neyman et al., Eds., “SEER Cancer Statistics Review, 1975–2006, National Cancer Institute,” November 2008, SEER data submission, posted to the SEER web site, Bethesda, Md, USA, 2009http://seer.cancer.gov/csr/1975_2006/.
  17. J. M. Connors, “Clinical manifestations and natural history of Hodgkin's lymphoma,” Cancer Journal, vol. 15, no. 2, pp. 124–128, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. V. Dinand and L. S. Arya, “Epidemiology of childhood Hodgkin's disease: is it different in developing countries?” Indian Pediatrics, vol. 43, no. 2, pp. 141–147, 2006. View at Google Scholar · View at Scopus
  19. N. Siddiqui, B. Ayub, F. Badar, and A. Zaidi, “Hodgkin's lymphoma in Pakistan: a clinico-epidemiological study of 658 cases at a cancer center in Lahore,” Asian Pacific Journal of Cancer Prevention, vol. 7, no. 4, pp. 651–655, 2006. View at Google Scholar · View at Scopus
  20. M. Karimi, H. Yarmohammadi, A. A. Ghavanini, and P. V. Kumar, “Epidemiological surveillance of pediatric Hodgkin's disease in southern Iran,” Medical Science Monitor, vol. 8, no. 8, pp. CR572–CR575, 2002. View at Google Scholar · View at Scopus
  21. G. Sissolak, D. Sissolak, and P. Jacobs, “Human immunodeficiency and Hodgkin lymphoma,” Transfusion and Apheresis Science, vol. 42, no. 2, pp. 131–139, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. N. Mounier, M. Spina, and J. P. Spano, “Hodgkin lymphoma in HIV positive patients,” Current HIV Research, vol. 8, no. 2, pp. 141–146, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Carbone, A. Gloghini, D. Serraino, and M. Spina, “HIV-associated Hodgkin lymphoma,” Current Opinion in HIV and AIDS, vol. 4, no. 1, pp. 3–10, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Gloghini and A. Carbone, “Why would the incidence of HIV-associated Hodgkin lymphoma increase in the setting of improved immunity?” International Journal of Cancer, vol. 120, no. 12, pp. 2753–2754, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. C. Palmieri, T. Treibel, O. Large, and M. Bower, “AIDS-related non-Hodgkin's lymphoma in the first decade of highly active antiretroviral therapy,” Quarterly Journal of Medicine, vol. 99, no. 12, pp. 811–826, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. S. J. Proctor, J. Wilkinson, and M. Sieniawski, “Hodgkin lymphoma in the elderly: a clinical review of treatment and outcome, past, present and future,” Critical Reviews in Oncology/Hematology, vol. 71, no. 3, pp. 222–232, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. N. Meyer, C. Paul, and L. Misery, “Pruritus in cutaneous T-cell lymphomas: frequent, often severe and difficult to treat,” Acta Dermato-Venereologica, vol. 90, no. 1, pp. 12–17, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. E. Weisshaar and F. Dalgard, “Epidemiology of itch: adding to the burden of skin morbidity,” Acta Dermato-Venereologica, vol. 89, no. 4, pp. 339–350, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. N. Hiramanek, “Itch: a symptom of occult disease,” Australian Family Physician, vol. 33, no. 7, pp. 495–499, 2004. View at Google Scholar · View at Scopus
  30. S. Omidvari, H. N. Khojasteh, M. Mohammadianpanah, A. Monabati, A. Mosalaei, and N. Ahmadloo, “Long-term pruritus as the initial and sole clinical manifestation of occult Hodgkin's disease,” Indian Journal of Medical Sciences, vol. 58, no. 6, pp. 250–252, 2004. View at Google Scholar · View at Scopus
  31. V. Stadie and W. C. H. Marsch, “Itching attacks with generalized hyperhydrosis as initial symptoms of Hodgkin's disease,” Journal of the European Academy of Dermatology and Venereology, vol. 17, no. 5, pp. 559–561, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. F. Cavalli, “Rare syndromes in Hodgkin's disease,” Annals of Oncology, vol. 9, no. 5, pp. S109–S113, 1998. View at Google Scholar · View at Scopus
  33. F. Gonçalves, “Thalidomide for the control of severe paraneoplastic pruritus associated with Hodgkin's disease,” American Journal of Hospice and Palliative Medicine, vol. 27, no. 7, pp. 486–487, 2010. View at Publisher · View at Google Scholar
  34. P. Radossi, T. Tison, F. Vianello, and F. Dazzi, “Intractable pruritus in non-Hodgkin lymphoma/CLL: rapid response to IFNα,” British Journal of Haematology, vol. 94, no. 3, p. 579, 1996. View at Google Scholar · View at Scopus
  35. J. O. Bichel and P. Bastrup-Madsen, “Alcohol pain in Hodgkin's disease,” Lancet, vol. 261, no. 6764, pp. 764–766, 1953. View at Google Scholar · View at Scopus
  36. J. de Winter, “Alcohol-induced pain in Hodgkin's disease,” British Medical Journal, vol. 2, pp. 604–605, 1953. View at Google Scholar
  37. C. Hall and K. Olson, “Alcohol-induced pain in Hodgkin's disease,” New England Journal of Medicine, vol. 253, pp. 608–609, 1955. View at Google Scholar
  38. H. Conn, “Alcohol-induced pain as a manifestation of Hodgkin's disease; an investigation of its specificity and frequency,” Archives of Internal Medicine, vol. 100, pp. 241–247, 1957. View at Google Scholar
  39. W. E. Braun and B. I. Shnider, “Alcohol-induced pain in Hodgkin's disease,” Journal of the American Medical Association, vol. 168, no. 14, pp. 1882–1885, 1958. View at Google Scholar · View at Scopus
  40. A. H. James, “Hodgkin's disease with and without alcohol-induced pain. A clinical and histological comparison,” Quarterly Journal of Medicine, vol. 29, pp. 47–66, 1960. View at Google Scholar · View at Scopus
  41. J. Wanka, “Alcohol-induced pain associated with adenocarcinoma of the bronchus,” British Medical Journal, vol. 2, pp. 88–89, 1965. View at Google Scholar
  42. T. B. Brewin, “Alcohol intolerance in neoplastic disease,” British Medical Journal, vol. 5511, pp. 437–441, 1966. View at Google Scholar · View at Scopus
  43. J. Bichel, “Is the alcohol-intolerance syndrome in Hodgkin's disease disappearing?” Lancet, vol. 1, no. 7759, article 1069, 1972. View at Google Scholar · View at Scopus
  44. K. Atkinson, D. E. Austin, T. J. McElwain, and M. J. Peckham, “Alcohol pain in Hodgkin's disease,” Cancer, vol. 37, no. 2, pp. 895–899, 1976. View at Google Scholar · View at Scopus
  45. W. B. Ershler, R. W. Petry, G. R. Hafez, and J. T. Goswitz, “Alcohol-induced genital pain in recurrent Hodgkin's disease,” Journal of the American Medical Association, vol. 242, no. 10, article 1064, 1979. View at Publisher · View at Google Scholar · View at Scopus
  46. A. M. Bobrove, “Alcohol-related pain and Hodgkin's disease,” Western Journal of Medicine, vol. 138, no. 6, pp. 874–875, 1983. View at Google Scholar · View at Scopus
  47. B. C. Callahan, R. Coe, and H. M. Place, “Hodgkin disease of the spine presenting as alcohol-related pain. A case report and review of the literature,” Journal of Bone and Joint Surgery A, vol. 76, no. 1, pp. 119–121, 1994. View at Google Scholar · View at Scopus
  48. P. Custodi, A. Cerutti, R. Bagnato, and P. Cassani, “Alcohol-induced pain in tuberculous adenitis,” Haematologica, vol. 78, no. 6, pp. 416–417, 1993. View at Google Scholar · View at Scopus
  49. A. Sánchez-Aguilera, C. Montalbán, P. de la Cueva et al., “Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma,” Blood, vol. 108, no. 2, pp. 662–668, 2006. View at Publisher · View at Google Scholar · View at Scopus
  50. H. F. Miranda, J. C. Prieto, M. M. Puig, and G. Pinardi, “Isobolographic analysis of multimodal analgesia in an animal model of visceral acute pain,” Pharmacology Biochemistry and Behavior, vol. 88, no. 4, pp. 481–486, 2008. View at Publisher · View at Google Scholar · View at Scopus
  51. E. M. Richards and R. E. Marcus, “Difficulty in the staging of Hodgkin's disease due to the coexistence of reactive lymphadenopathy,” Leukemia and Lymphoma, vol. 9, no. 4-5, pp. 413–417, 1993. View at Google Scholar · View at Scopus
  52. I. T. Magrath, “Fine needle aspiration in the diagnosis of childhood malignant disease in Uganda,” British Journal of Cancer, vol. 28, no. 6, pp. 477–487, 1973. View at Google Scholar · View at Scopus
  53. T. F. Kardos, J. H. Vinson, F. G. Behm, W. J. Frable, and G. J. O'Dowd, “Hodgkin's disease: diagnosis by fine-needle aspiration biopsy: analysis of cytologic criteria from a selected series,” American Journal of Clinical Pathology, vol. 86, no. 3, pp. 286–291, 1986. View at Google Scholar · View at Scopus
  54. A. Flint, N. B. Kumar, and B. Naylor, “Pulmonary Hodgkin's disease. Diagnosis by fine needle aspiration,” Acta Cytologica, vol. 32, no. 2, pp. 221–225, 1988. View at Google Scholar · View at Scopus
  55. F. Fulciniti, P. Zeppa, A. Vetrani, G. Troncone, and L. Palombini, “Hodgkin's disease mimicking suppurative lymphadenitis: a possible pitfall in fine-needle aspiration biopsy cytology,” Diagnostic cytopathology, vol. 5, no. 3, pp. 282–285, 1989. View at Google Scholar · View at Scopus
  56. C. Corrigan, C. Sewell, and A. Martin, “Recurrent Hodgkin's disease in the breast. Diagnosis of a case by fine needle aspiration and immunocytochemistry,” Acta Cytologica, vol. 34, no. 5, pp. 669–672, 1990. View at Google Scholar · View at Scopus
  57. D. K. Das and S. K. Gupta, “Fine needle aspiration cytodiagnosis of Hodgkin's disease and its subtypes. II. Subtyping by differential cell counts,” Acta Cytologica, vol. 34, no. 3, pp. 337–341, 1990. View at Google Scholar · View at Scopus
  58. R. Granados, G. S. Pinkus, P. West, and E. S. Cibas, “Hodgkin's disease presenting as an enlarged thyroid gland. Report of a case diagnosed by fine needle aspiration,” Acta Cytologica, vol. 35, no. 4, pp. 439–442, 1991. View at Google Scholar · View at Scopus
  59. A. Vailati, C. Marena, L. Aristia, A. Nelva, C. Cebrelli, and E. Ferrari, “Primary Hodgkin's disease of the thyroid: report of a case and a review of the literature,” Haematologica, vol. 76, no. 1, pp. 69–71, 1991. View at Google Scholar · View at Scopus
  60. P. J. Kragel, L. K. Miller, and D. Casafrancisco, “Aspiration cytology of lymphocyte-depleted Hodgkin's lymphoma in a man infected with the human immunodeficiency virus: a case report,” Acta Cytologica, vol. 36, no. 3, pp. 395–398, 1992. View at Google Scholar · View at Scopus
  61. D. L. Krasne, W. Y. Naritoku, and M. M. Cosgrove, “Diagnosis of syncytial (lacunar cell-predominant) nodular sclerosing Hodgkin's disease by fine needle aspiration: a case report,” Acta Cytologica, vol. 37, no. 3, pp. 418–422, 1993. View at Google Scholar · View at Scopus
  62. F. Fulciniti, A. Vetrani, P. Zeppa et al., “Hodgkin's disease: diagnostic accuracy of fine needle aspiration: a report based on 62 consecutive cases,” Cytopathology, vol. 5, no. 4, pp. 226–233, 1994. View at Google Scholar · View at Scopus
  63. D. Daskalopoulou, D. Tamiolakis, S. Tsousis, N. Apostolikas, and S. Markidou, “Sources of discrepancies in the diagnosis of Hodgkin's disease by fine needle aspiration,” Archives d'Anatomie et de Cytologie Pathologiques, vol. 44, no. 4, pp. 166–173, 1996. View at Google Scholar · View at Scopus
  64. L. E. Grosso, B. T. Collins, C. H. Dunphy, and R. R. Ramos, “Lymphocyte-depleted Hodgkin's disease: diagnostic challenges by fine- needle aspiration,” Diagnostic Cytopathology, vol. 19, no. 1, pp. 66–69, 1998. View at Publisher · View at Google Scholar · View at Scopus
  65. J. D. Lewis, D. O. Faigel, Y. Dowdy et al., “Hodgkin's disease diagnosed by endoscopic ultrasound-guided fine needle aspiration of a periduodenal lymph node,” American Journal of Gastroenterology, vol. 93, no. 5, pp. 834–836, 1998. View at Publisher · View at Google Scholar · View at Scopus
  66. D. C. Chhieng, J. F. Cangiarella, W. F. Symmans, and J. M. Cohen, “Fine-needle aspiration cytology of Hodgkin disease: a study of 89 cases with emphasis on the false-negative cases,” Cancer, vol. 93, no. 1, pp. 52–59, 2001. View at Publisher · View at Google Scholar
  67. W. S. Moreland and K. R. Geisinger, “Utility and outcomes of fine-needle aspiration biopsy in Hodgkin's disease,” Diagnostic Cytopathology, vol. 26, no. 5, pp. 278–282, 2002. View at Publisher · View at Google Scholar · View at Scopus
  68. Y. C. Oertel, “Fine needle aspiration in Hodgkin's disease,” Acta Cytologica, vol. 46, no. 3, article 617, 2002. View at Google Scholar · View at Scopus
  69. J. R. Zhang, A. S. Raza, T. S. Greaves, and C. J. Cobb, “Fine-needle aspiration diagnosis of Hodgkin lymphoma using current WHO classification—re-evaluation of cases from 1999–2004 with new proposals,” Diagnostic Cytopathology, vol. 34, no. 6, pp. 397–402, 2006. View at Publisher · View at Google Scholar · View at Scopus
  70. P. Zeppa, M. Picardi, I. Cozzolino et al., “Fine-needle aspiration cytology in the follow-up of Hodgkin lymphoma,” Diagnostic Cytopathology, vol. 36, no. 7, pp. 467–472, 2008. View at Publisher · View at Google Scholar · View at Scopus
  71. D. K. Das, I. M. Francis, P. N. Sharma et al., “Hodgkin's lymphoma: diagnostic difficulties in fine-needle aspiration cytology,” Diagnostic Cytopathology, vol. 37, no. 8, pp. 564–573, 2009. View at Publisher · View at Google Scholar · View at Scopus
  72. A. E. Walts, “Fine-needle aspiration of extranodal Hodgkin's lymphoma misinterpreted as carcinoma,” Diagnostic Cytopathology, vol. 37, no. 4, pp. 313–314, 2009. View at Publisher · View at Google Scholar · View at Scopus
  73. S. O. Kolonić, K. Prasek-Kudrna, V. Roso et al., “Value of fine-needle aspiration cytology in diagnosis of Hodgkin's lymphoma and anaplastic large cell lymphoma: one centre experience,” Collegium Antropologicum, vol. 34, no. 1, pp. 75–79, 2010. View at Google Scholar · View at Scopus
  74. R. D. Woodruff, “Reviewing histologic diagnosis of lymphoma. Comparison of original and review diagnoses in 269 cases,” Archives of Pathology and Laboratory Medicine, vol. 105, no. 11, pp. 573–576, 1981. View at Google Scholar · View at Scopus
  75. T. P. Miller, G. E. Byrne, and S. J. Jones, “Mistaken clinical and pathologic diagnoses of Hodgkin's disease: a Southwest Oncology Group Study,” Cancer Treatment Reports, vol. 66, no. 4, pp. 645–651, 1982. View at Google Scholar · View at Scopus
  76. S. L. Glaser, R. F. Dorfman, and C. A. Clarke, “Expert review of the diagnosis and histologic classification of Hodgkin disease in a population-based cancer registry: Interobserver reliability and impact on incidence and survival rates,” Cancer, vol. 92, no. 2, pp. 218–224, 2001. View at Publisher · View at Google Scholar · View at Scopus
  77. R. M. Braziel and K. Oyama, “Mistaken diagnoses of Hodgkin's disease,” Hematology/Oncology Clinics of North America, vol. 11, no. 5, pp. 863–892, 1997. View at Publisher · View at Google Scholar · View at Scopus
  78. J. Bernhards, R. Fischer, K. Hubner, E.-W. Schwarze, and A. Georgii, “Histopathological classification of Hodgkin's lymphomas,” Annals of Oncology, vol. 3, supplement 4, pp. S31–S33, 1992. View at Google Scholar
  79. A. Georgii, R. Fischer, K. Hubner, E. W. Schwarze, and J. Bernhards, “Classification of Hodgkin's disease biopsies by a panel of four histopathologists: report of 1,140 patients from the German national trial,” Leukemia and Lymphoma, vol. 9, no. 4-5, pp. 365–370, 1993. View at Google Scholar · View at Scopus
  80. K. O. Franssila, M. K. Heiskala, and H. J. Heiskala, “Epidemiology and histopathology of Hodgkin's disease in Finland,” Cancer, vol. 39, no. 3, pp. 1280–1288, 1977. View at Google Scholar · View at Scopus
  81. L. R. Matz, L. R. Finlay-Jones, E. D. Waters et al., “The Rye classification of a population based series of Hodgkin's disease patients in Western Australia,” Pathology, vol. 13, no. 2, pp. 267–276, 1981. View at Google Scholar
  82. K. Dunleavy, S. Pittaluga, N. Grant et al., “Gray zone lymphomas: clinical and histological characteristics and treatment with dose-adjusted-EPOCH-R (Abstract # 3590),” in Proceedings of the 50th ASH Annual Meeting, San Frncisco, Calif, USA, 2008.
  83. K. R. Calvo, A. Traverse-Glehen, S. Pittaluga, and E. S. Jaffe, “Molecular profiling provides evidence of primary mediastinal large B-cell lymphoma as a distinct entity related to classic Hodgkin lymphoma: implications for mediastinal gray zone lymphomas as an intermediate form of B-cell lymphoma,” Advances in Anatomic Pathology, vol. 11, no. 5, pp. 227–238, 2004. View at Google Scholar · View at Scopus
  84. K. J. Savage, “Rare B-cell lymphomas: primary mediastinal, intravascular, and primary effusion lymphoma,” Cancer Treatment and Research, vol. 142, pp. 243–264, 2008. View at Google Scholar · View at Scopus
  85. K. J. Savage, “Primary mediastinal large B-cell lymphoma,” Oncologist, vol. 11, no. 5, pp. 488–495, 2006. View at Publisher · View at Google Scholar · View at Scopus
  86. K. J. Savage, N. Al-Rajhi, N. Voss et al., “Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience,” Annals of Oncology, vol. 17, no. 1, pp. 123–130, 2006. View at Publisher · View at Google Scholar · View at Scopus
  87. F. Feuerhake, J. L. Kutok, S. Monti et al., “NFκB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes,” Blood, vol. 106, no. 4, pp. 1392–1399, 2005. View at Publisher · View at Google Scholar · View at Scopus
  88. K. J. Savage, S. Monti, J. L. Kutok et al., “The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma,” Blood, vol. 102, no. 12, pp. 3871–3879, 2003. View at Publisher · View at Google Scholar · View at Scopus
  89. T. Rudiger, E. S. Jaffe, G. Delsol et al., “Workshop report on Hodgkin's disease and related diseases ('grey zone' lymphoma),” Annals of Oncology, vol. 9, no. 5, pp. S31–S38, 1998. View at Google Scholar · View at Scopus
  90. L. Boudová, E. Torlakovic, J. Delabie et al., “Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell/histiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma,” Blood, vol. 102, no. 10, pp. 3753–3758, 2003. View at Publisher · View at Google Scholar · View at Scopus
  91. M. S. Lim, M. Beaty, L. Sorbara et al., “T-cell/histiocyte-rich large B-cell lymphoma: a heterogeneous entity with derivation from germinal center B cells,” American Journal of Surgical Pathology, vol. 26, no. 11, pp. 1458–1466, 2002. View at Publisher · View at Google Scholar · View at Scopus
  92. F. Zhao, “Nodular lymphocyte-predominant Hodgkin lymphoma or T-cell/histiocyte rich large B-cell lymphoma: the problem in "grey zone" lymphomas,” International Journal of Clinical and Experimental Pathology, vol. 1, pp. 300–305, 2008. View at Google Scholar
  93. A. Carbone, A. Gloghini, A. Aiello, A. Testi, and A. Cabras, “B-cell lymphomas with features intermediate between distinct pathologic entities. From pathogenesis to pathology,” Human Pathology, vol. 41, no. 5, pp. 621–631, 2010. View at Publisher · View at Google Scholar · View at Scopus
  94. J. R. Fromm, A. Thomas, and B. L. Wood, “Flow cytometry can diagnose classical Hodgkin lymphoma in lymph nodes with high sensitivity and specificity,” American Journal of Clinical Pathology, vol. 131, no. 3, pp. 322–332, 2009. View at Publisher · View at Google Scholar · View at Scopus
  95. J. R. Fromm, S. J. Kussick, and B. L. Wood, “Identification and purification of classical Hodgkin cells from lymph nodes by flow cytometry and flow cytometric cell sorting,” American Journal of Clinical Pathology, vol. 126, no. 5, pp. 764–780, 2006. View at Publisher · View at Google Scholar · View at Scopus
  96. M. L. Hansmann and R. Kuppers, “Pathology and 'molecular histology' of Hodgkin's disease and the border to non-Hodgkin's lymphomas,” Bailliere's Clinical Haematology, vol. 9, no. 3, pp. 459–477, 1996. View at Publisher · View at Google Scholar · View at Scopus
  97. A. Jox, J. Wolf, and V. Diehl, “Hodgkin's disease biology: recent advances,” Hematological Oncology, vol. 15, no. 4, pp. 165–171, 1997. View at Publisher · View at Google Scholar · View at Scopus
  98. H. Stein, M. Hummel, T. Marafioti, I. Anagnostopoulos, and H. D. Foss, “Molecular biology of Hodgkin's disease,” Cancer Surveys, vol. 30, pp. 107–123, 1997. View at Google Scholar · View at Scopus
  99. T. Marafioti, M. Hummel, H. D. Foss et al., “Hodgkin and Reed-Sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription,” Blood, vol. 95, no. 4, pp. 1443–1450, 2000. View at Google Scholar · View at Scopus
  100. R. Küppers, I. Schwering, A. Bräuninger, K. Rajewsky, and M. L. Hansmann, “Biology of Hodgkin's lymphoma,” Annals of Oncology, vol. 13, no. 1, pp. 11–18, 2002. View at Google Scholar · View at Scopus
  101. R. K. Thomas, D. Re, J. Wolf, and V. Diehl, “Part I: Hodgkin's lymphoma—molecular biology of Hodgkin and Reed-Sternberg cells,” Lancet Oncology, vol. 5, no. 1, pp. 11–18, 2004. View at Publisher · View at Google Scholar · View at Scopus
  102. A. Bräuninger, R. Schmitz, D. Bechtel, C. Renné, M. L. Hansmann, and R. Küppers, “Molecular biology of Hodgkin's and Reed/Sternberg cells in Hodgkin's lymphoma,” International Journal of Cancer, vol. 118, no. 8, pp. 1853–1861, 2006. View at Publisher · View at Google Scholar · View at Scopus
  103. M. Müschen, K. Rajewsky, A. Bräuninger et al., “Rare occurrence of classical Hodgkin's disease as a T cell lymphoma,” Journal of Experimental Medicine, vol. 191, no. 2, pp. 387–394, 2000. View at Publisher · View at Google Scholar · View at Scopus
  104. V. Seitz, M. Hummel, T. Marafioti, I. Anagnostopoulos, C. Assaf, and H. Stein, “Detection of clonal T-cell receptor gamma-chain gene rearrangements Reed-Sternberg cells of classic Hodgkin disease,” Blood, vol. 95, no. 10, pp. 3020–3024, 2000. View at Google Scholar · View at Scopus
  105. C. B. Hertel, X. G. Zhou, S. J. Hamilton-Dutoit, and S. Junker, “Loss of B cell identity correlates with loss of B cell-specific transcription factors in Hodgkin/Reed-Sternberg cells of classical Hodgkin lymphoma,” Oncogene, vol. 21, no. 32, pp. 4908–4920, 2002. View at Publisher · View at Google Scholar · View at Scopus
  106. J. R. Doerr, C. S. Malone, F. M. Fike et al., “Patterned CpG methylation of silenced B cell gene promoters in classical Hodgkin lymphoma-derived and primary effusion lymphoma cell lines,” Journal of Molecular Biology, vol. 350, no. 4, pp. 631–640, 2005. View at Google Scholar · View at Scopus
  107. A. Ushmorov, F. Leithäuser, O. Sakk et al., “Epigenetic processes play a major role in B-cell-specific gene silencing in classical Hodgkin lymphoma,” Blood, vol. 107, no. 6, pp. 2493–2500, 2006. View at Publisher · View at Google Scholar · View at Scopus
  108. A. Ushmorov, O. Ritz, M. Hummel et al., “Epigenetic silencing of the immunoglobulin heavy-chain gene in classical Hodgkin lymphoma-derived cell lines contributes to the loss of immunoglobulin expression,” Blood, vol. 104, no. 10, pp. 3326–3334, 2004. View at Publisher · View at Google Scholar · View at Scopus
  109. F. Jundt, I. Anagnostopoulos, R. Förster, S. Mathas, H. Stein, and B. Dörken, “Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma,” Blood, vol. 99, no. 9, pp. 3398–3403, 2002. View at Publisher · View at Google Scholar · View at Scopus
  110. S. Mathas, “The pathogenesis of classical Hodgkin's lymphoma: a model for B-cell plasticity,” Hematology/Oncology Clinics of North America, vol. 21, no. 5, pp. 787–804, 2007. View at Publisher · View at Google Scholar · View at Scopus
  111. A. Ehlers, E. Oker, S. Bentink, D. Lenze, H. Stein, and M. Hummel, “Histone acetylation and DNA demethylation of B cells result in a Hodgkin-like phenotype,” Leukemia, vol. 22, no. 4, pp. 835–841, 2008. View at Publisher · View at Google Scholar · View at Scopus
  112. R. Küppers, “Molecular biology of Hodgkin's lymphoma,” Advances in Cancer Research, vol. 84, pp. 277–312, 2002. View at Publisher · View at Google Scholar · View at Scopus
  113. A. Braeuninger, R. Küppers, J. G. Strickler, H. H. Wacker, K. Rajewsky, and M. L. Hansmann, “Hodgkin and Reed-Sternberg cells in lymphocyte predominant Hodgkin disease represent clonal populations of germinal center-derived tumor B cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 17, pp. 9337–9342, 1997. View at Publisher · View at Google Scholar · View at Scopus
  114. B. Falini, B. Bigerna, L. Pasqualucci et al., “Distinctive expression pattern of the BCL-6 protein in nodular lymphocyte predominance Hodgkin's disease,” Blood, vol. 87, no. 2, pp. 465–471, 1996. View at Google Scholar · View at Scopus
  115. S. Montes-Moreno, G. Roncador, L. Maestre et al., “Gcet1 (centerin), a highly restricted marker for a subset of germinal center-derived lymphomas,” Blood, vol. 111, no. 1, pp. 351–358, 2008. View at Publisher · View at Google Scholar · View at Scopus
  116. A. Dogan, E. Bagdi, P. Munson, and P. G. Isaacson, “CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas,” American Journal of Surgical Pathology, vol. 24, no. 6, pp. 846–852, 2000. View at Publisher · View at Google Scholar · View at Scopus
  117. N. Masir, T. Marafioti, M. Jones et al., “Loss of CD19 expression in B-cell neoplasms,” Histopathology, vol. 48, no. 3, pp. 239–246, 2006. View at Publisher · View at Google Scholar · View at Scopus
  118. S. Tedoldi, A. Mottok, J. Ying et al., “Selective loss of B-cell phenotype in lymphocyte predominant Hodgkin lymphoma,” Journal of Pathology, vol. 213, no. 4, pp. 429–440, 2007. View at Publisher · View at Google Scholar · View at Scopus
  119. C. Renné, J. I. Martín-Subero, M.-L. Hansmann, and R. Siebert, “Molecular cytogenetic analyses of immunoglubulin loci in nodular lymphocyte predominant Hodgkin's lymphoma reveal a recurrent IGH-BCL6 juxtaposition,” Journal of Molecular Diagnostics, vol. 7, no. 3, pp. 352–356, 2005. View at Google Scholar
  120. I. Wlodarska, P. Nooyen, B. Maes et al., “Frequent occurrence of BCL6 rearrangements in nodular lymphocyte predominance Hodgkin lymphoma but not in classical Hodgkin lymphoma,” Blood, vol. 101, no. 2, pp. 706–710, 2003. View at Publisher · View at Google Scholar · View at Scopus
  121. M. A. Epstein, B. G. Achong, and Y. M. Barr, “Virus particles in cultured lymphoblasts from Burkitt's lymphoma,” Lancet, vol. 283, no. 7335, pp. 702–703, 1964. View at Google Scholar · View at Scopus
  122. V. Diehl, G. Henle, W. Henle, and G. Kohn, “Demonstration of a herpes group virus in cultures of peripheral leukocytes from patients with infectious mononucleosis,” Journal of Virology, vol. 2, no. 7, pp. 663–669, 1968. View at Google Scholar · View at Scopus
  123. G. Henle, W. Henle, and V. Diehl, “Relation of Burkitt's tumor-associated herpes-ytpe virus to infectious mononucleosis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 59, no. 1, pp. 94–101, 1968. View at Google Scholar · View at Scopus
  124. L. M. Weiss, L. A. Movahed, R. A. Warnke, and J. Sklar, “Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease,” New England Journal of Medicine, vol. 320, no. 8, pp. 502–506, 1989. View at Google Scholar · View at Scopus
  125. S. Uccini, F. Monardo, A. Stoppacciaro et al., “High frequency of Epstein-Barr virus genome detection in Hodgkin's disease of HIV-positive patients,” International Journal of Cancer, vol. 46, no. 4, pp. 581–585, 1990. View at Google Scholar · View at Scopus
  126. H. Uhara, Y. Sato, K. Mukai et al., “Detection of Epstein-Barr virus DNA in Reed-Sternberg cells of Hodgkin's disease using the polymerase chain reaction and in situ hybridization,” Japanese Journal of Cancer Research, vol. 81, no. 3, pp. 272–278, 1990. View at Google Scholar · View at Scopus
  127. T. C. Wu, R. B. Mann, P. Charache et al., “Detection of EBV gene expression in Reed-Sternberg cells of Hodgkin's disease,” International Journal of Cancer, vol. 46, no. 5, pp. 801–804, 1990. View at Publisher · View at Google Scholar · View at Scopus
  128. P. Brousset, S. Chittal, D. Schlaifer et al., “Detection of Epstein-Barr virus messenger RNA in Reed-Sternberg cells of Hodgkin's disease by in situ hybridization with biotinylated probes on specially processed modified acetone methyl benzoate xylene (ModAMeX) sections,” Blood, vol. 77, no. 8, pp. 1781–1786, 1991. View at Google Scholar · View at Scopus
  129. P. J. Coates, G. Slavin, and A. J. D'Ardenne, “Persistence of Epstein-Barr virus in Reed-Sternberg cells throughout the course of Hodgkin's disease,” Journal of Pathology, vol. 164, no. 4, pp. 291–297, 1991. View at Google Scholar · View at Scopus
  130. H. Herbst, F. Dallenbach, M. Hummel et al., “Epstein-Barr virus latent membrane protein expression in Hodgkin and Reed-Sternberg cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 11, pp. 4766–4770, 1991. View at Google Scholar · View at Scopus
  131. R. F. Jarrett, A. Gallagher, D. B. Jones et al., “Detection of Epstein-Barr virus genomes in Hodgkin's disease: relation to age,” Journal of Clinical Pathology, vol. 44, no. 10, pp. 844–848, 1991. View at Google Scholar · View at Scopus
  132. A. Masih, D. Weisenburger, M. Duggan et al., “Epstein-Barr viral genome in lymph nodes from patients with Hodgkin's disease may not be specific to Reed-Sternberg cells,” American Journal of Pathology, vol. 139, no. 1, pp. 37–43, 1991. View at Google Scholar · View at Scopus
  133. M. Boiocchi, V. De Re, R. Dolcetti, A. Carbone, A. Scarpa, and F. Menestrina, “Association of Epstein-Barr virus genome with mixed cellularity and cellular phase nodular sclerosis Hodgkin's disease subtypes,” Annals of Oncology, vol. 3, no. 4, pp. 307–310, 1992. View at Google Scholar · View at Scopus
  134. G. Khan, P. J. Coates, H. O. Kangro, and G. Slavin, “Epstein Barr virus (EBV) encoded small RNAs: targets for detection by in situ hybridisation with oligonucleotide probes,” Journal of Clinical Pathology, vol. 45, no. 7, pp. 616–620, 1992. View at Google Scholar · View at Scopus
  135. H. Knecht, D. J. L. Joske, E. Bachmann, R. Sahli, and B. F. Odermatt, “Significance of the detection of Epstein-Barr virus DNA in lymph nodes in patients with Hodgkin's disease,” Leukemia and Lymphoma, vol. 8, no. 4-5, pp. 319–325, 1992. View at Google Scholar · View at Scopus
  136. N. Teramoto, T. Akagi, T. Yoshino, K. Takahashi, and H. J. Jeon, “Direct detection of Epstein-Barr virus DNA from a single Reed-Sternberg cell of Hodgkin's disease by polymerase chain reaction,” Japanese Journal of Cancer Research, vol. 83, no. 4, pp. 329–333, 1992. View at Google Scholar · View at Scopus
  137. C. Bellas, F. Mampaso, G. Fraile, A. Molina, T. Bricio, and C. Cuesta, “Detection of Epstein-Barr genome in the lymph nodes of Hodgkin's disease,” Postgraduate Medical Journal, vol. 69, no. 818, pp. 916–919, 1993. View at Google Scholar · View at Scopus
  138. A. Carbone, A. Gloghini, I. Zanette, B. Canal, A. Rizzo, and R. Volpe, “Co-expression of Epstein-Barr virus latent membrane protein and vimentin in 'aggressive' histological subtypes of Hodgkin's disease,” Virchows Archiv, vol. 422, no. 1, pp. 39–45, 1993. View at Google Scholar · View at Scopus
  139. P. J. Coates, A. J. D'Ardenne, G. Slavin, J. E. Kingston, and J. S. Malpas, “Detection of Epstein-Barr virus in Reed-Sternberg cells of Hodgkin's disease arising in children,” Medical and Pediatric Oncology, vol. 21, no. 1, pp. 19–23, 1993. View at Publisher · View at Google Scholar · View at Scopus
  140. G. Kapatai and P. Murray, “Contribution of the Epstein-Barr virus to the molecular pathogenesis of Hodgkin lymphoma,” Journal of Clinical Pathology, vol. 60, no. 12, pp. 1342–1349, 2007. View at Publisher · View at Google Scholar · View at Scopus
  141. J. I. Cohen, “Epstein-Barr virus infection,” New England Journal of Medicine, vol. 343, no. 7, pp. 481–492, 2000. View at Publisher · View at Google Scholar · View at Scopus
  142. S. L. Glaser, R. J. Lin, S. L. Stewart et al., “Epstein-Barr virus-associated Hodgkin's disease: epidemiologic characteristics in international data,” International Journal of Cancer, vol. 70, no. 4, pp. 375–382, 1997. View at Publisher · View at Google Scholar · View at Scopus
  143. P. G. Murray, L. J. Billingham, H. T. Hassan et al., “Effect of Epstein-Barr virus infection on response to chemotherapy and survival in Hodgkin's disease,” Blood, vol. 94, no. 2, pp. 442–447, 1999. View at Google Scholar · View at Scopus
  144. K. J. Flavell, L. J. Billingham, J. P. Biddulph et al., “The effect of Epstein-Barr virus status on outcome in age- and sex-defined subgroups of patients with advanced Hodgkin's disease,” Annals of Oncology, vol. 14, no. 2, pp. 282–290, 2003. View at Publisher · View at Google Scholar · View at Scopus
  145. R. F. Jarrett, G. L. Stark, J. White et al., “Impact of tumor Epstein-Barr virus status on presenting features and outcome in age-defined subgroups of patients with classic Hodgkin lymphoma: a population-based study,” Blood, vol. 106, no. 7, pp. 2444–2451, 2005. View at Publisher · View at Google Scholar
  146. P. M. Kamper, E. Kjeldsen, N. Clausen, K. Bendix, S. Hamilton-Dutoit, and F. D'Amore, “Epstein-Barr virus-associated familial Hodgkin lymphoma: paediatric onset in three of five siblings,” British Journal of Haematology, vol. 129, no. 5, pp. 615–617, 2005. View at Publisher · View at Google Scholar · View at Scopus
  147. A. Diepstra, M. Niens, E. Vellenga et al., “Association with HLA class I in Epstein-Barr-virus-positive and with HLA class III in Epstein-Barr-virus-negative Hodgkin's lymphoma,” Lancet, vol. 365, no. 9478, pp. 2216–2224, 2005. View at Publisher · View at Google Scholar · View at Scopus
  148. A. Diepstra, G. W. van Imhoff, H. E. Karim-Kos et al., “HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin's lymphoma,” Journal of Clinical Oncology, vol. 25, no. 21, pp. 3101–3108, 2007. View at Publisher · View at Google Scholar · View at Scopus
  149. M. Niens, R. F. Jarrett, B. Hepkema et al., “HLA-A*02 is associated with a reduced risk and HLA-A*01 with an increased risk of developing EBV + Hodgkin lymphoma,” Blood, vol. 110, no. 9, pp. 3310–3315, 2007. View at Publisher · View at Google Scholar · View at Scopus
  150. J. D. Fingeroth, J. J. Weis, T. F. Tedder, J. L. Strominger, P. A. Biro, and D. T. Fearon, “Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2,” Proceedings of the National Academy of Sciences of the United States of America, vol. 81, no. 14, pp. 4510–4514, 1984. View at Google Scholar
  151. Q. Li, M. K. Spriggs, S. Kovats et al., “Epstein-Barr virus uses HLA class II as a cofactor for infection of B lymphocytes,” Journal of Virology, vol. 71, no. 6, pp. 4657–4662, 1997. View at Google Scholar · View at Scopus
  152. G. R. Nemerow, C. Mold, V. K. Schwend, V. Tollefson, and N. R. Cooper, “Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d,” Journal of Virology, vol. 61, no. 5, pp. 1416–1420, 1987. View at Google Scholar
  153. G. J. Babcock, L. L. Decker, R. B. Freeman, and D. A. Thorley-Lawson, “Epstein-Barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients,” Journal of Experimental Medicine, vol. 190, no. 4, pp. 567–576, 1999. View at Publisher · View at Google Scholar · View at Scopus
  154. G. J. Babcock, L. L. Decker, M. Volk, and D. A. Thorley-Lawson, “EBV persistence in memory B cells in vivo,” Immunity, vol. 9, no. 3, pp. 395–404, 1998. View at Publisher · View at Google Scholar · View at Scopus
  155. E. Kieff, “Epstein-Barr virus and its replication,” in Virology, B. N. Fields, D. M. Knipe, P. M. Howley et al., Eds., pp. 2343–2396, Lippincott-Raven, Philadelphia, Pa, USA, 1996. View at Google Scholar
  156. A. L. N. Chapman and A. B. Rickinson, “Epstein-Barr virus in Hodgkin's disease,” Annals of Oncology, vol. 9, no. 5, pp. S5–S16, 1998. View at Google Scholar · View at Scopus
  157. I. Miyazaki, R. K. Cheung, and H. M. Dosch, “Viral interleukin 10 is critical for the induction of B cell growth transformation by Epstein-Barr virus,” Journal of Experimental Medicine, vol. 178, no. 2, pp. 439–447, 1993. View at Google Scholar · View at Scopus
  158. S. B. A. Cohen, J. B. Crawley, M. C. Kahan, M. Feldmann, and B. M. J. Foxwell, “Interleukin-10 rescues T cells from apoptotic cell death: association with an upregulation of Bcl-2,” Immunology, vol. 92, no. 1, pp. 1–5, 1997. View at Google Scholar · View at Scopus
  159. D. F. Fiorentino, A. Zlotnik, T. R. Mosmann, M. Howard, and A. O'Garra, “IL-10 inhibits cytokine production by activated macrophages,” Journal of Immunology, vol. 147, no. 11, pp. 3815–3822, 1991. View at Google Scholar · View at Scopus
  160. D. F. Fiorentino, A. Zlotnik, P. Vieira et al., “IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells,” Journal of Immunology, vol. 146, no. 10, pp. 3444–3451, 1991. View at Google Scholar · View at Scopus
  161. S. Hohaus, M. Giachelia, A. Di Febo et al., “Polymorphism in cytokine genes as prognostic markers in Hodgkin's lymphoma,” Annals of Oncology, vol. 18, no. 8, pp. 1376–1381, 2007. View at Publisher · View at Google Scholar · View at Scopus
  162. E. Kilger, A. Kieser, M. Baumann, and W. Hammerschmidt, “Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor,” EMBO Journal, vol. 17, no. 6, pp. 1700–1709, 1998. View at Publisher · View at Google Scholar · View at Scopus
  163. C. Mancao and W. Hammerschmidt, “Epstein-Barr virus latent membrane protein 2A is a B-cell receptor mimic and essential for B-cell survival,” Blood, vol. 110, no. 10, pp. 3715–3721, 2007. View at Publisher · View at Google Scholar · View at Scopus
  164. G. Klein, E. Klein, and E. Kashuba, “Interaction of Epstein-Barr virus (EBV) with human B-lymphocytes,” Biochemical and Biophysical Research Communications, vol. 396, no. 1, pp. 67–73, 2010. View at Publisher · View at Google Scholar · View at Scopus
  165. M. A. Calderwood, K. Venkatesan, L. Xing et al., “Epstein-Barr virus and virus human protein interaction maps,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 18, pp. 7606–7611, 2007. View at Publisher · View at Google Scholar · View at Scopus
  166. F. M. Fadlelmola, M. Zhou, R. J. de Leeuw et al., “Sub-megabase resolution tiling (SMRT) array-based comparative genomic hybridization profiling reveals novel gains and losses of chromosomal regions in Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma cell lines,” Molecular Cancer, vol. 7, article 2, 2008. View at Publisher · View at Google Scholar · View at Scopus
  167. S. Hartmann, J. I. Martin-Subero, S. Gesk et al., “Detection of genomic imbalances in microdissected Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma by array-based comparative genomic hybridization,” Haematologica, vol. 93, no. 9, pp. 1318–1326, 2008. View at Publisher · View at Google Scholar · View at Scopus
  168. C. Steidl, A. Telenius, S. P. Shah et al., “Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome,” Blood, vol. 116, no. 3, pp. 418–427, 2010. View at Publisher · View at Google Scholar
  169. E. M. Leslie, R. G. Deeley, and S. P. C. Cole, “Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters,” Toxicology, vol. 167, no. 1, pp. 3–23, 2001. View at Publisher · View at Google Scholar · View at Scopus
  170. M. F. Rosenberg, Q. Mao, A. Holzenburg, R. C. Ford, R. G. Deeley, and S. P. C. Cole, “The structure of the multidrug resistance protein 1 (MRP1/ABCC1): crystallization and single-particle analysis,” Journal of Biological Chemistry, vol. 276, no. 19, pp. 16076–16082, 2001. View at Publisher · View at Google Scholar · View at Scopus
  171. E. Devilard, F. Bertucci, P. Trempat et al., “Gene expression profiling defines molecular subtypes of classical Hodgkin's disease,” Oncogene, vol. 21, no. 19, pp. 3095–3102, 2002. View at Publisher · View at Google Scholar · View at Scopus
  172. J. Kirchner and M. J. Bevan, “ITM2A is induced during thymocyte selection and T cell activation and causes downregulation of CD8 when overexpressed in CD4+CD8+ double positive thymocytes,” Journal of Experimental Medicine, vol. 190, no. 2, pp. 217–228, 1999. View at Publisher · View at Google Scholar · View at Scopus
  173. Y. Terai, M. Abe, K. Miyamoto et al., “Vascular smooth muscle cell growth-promoting factor/F-spondin inhibits angiogenesis via the blockade of integrin αvβ3 on vascular endothelial cells,” Journal of Cellular Physiology, vol. 188, no. 3, pp. 394–402, 2001. View at Publisher · View at Google Scholar · View at Scopus
  174. K. Miyamoto, Y. Morishita, M. Yamazaki et al., “Isolation and characterization of vascular smooth muscle cell growth promoting factor from bovine ovarian follicular fluid and its cDNA cloning from bovine and human ovary,” Archives of Biochemistry and Biophysics, vol. 390, no. 1, pp. 93–100, 2001. View at Publisher · View at Google Scholar · View at Scopus
  175. W. Ruf, N. Yokota, and F. Schaffner, “Tissue factor in cancer progression and angiogenesis,” Thrombosis research, vol. 125, supplement 2, pp. S36–38, 2010. View at Google Scholar
  176. A. Shinkai, M. Komuta-Kunitomo, N. Sato-Nakamura, and H. Anazawa, “N-terminal domain of eotaxin-3 is important for activation of CC chemokine receptor 3,” Protein Engineering, vol. 15, no. 11, pp. 923–929, 2002. View at Google Scholar · View at Scopus
  177. A. Shinkai, H. Yoshisue, M. Koike et al., “A novel human CC chemokine eotaxin-3, which is expressed in IL-4- stimulated vascular endothelial cells, exhibits potent activity toward eosinophils,” Journal of Immunology, vol. 163, no. 3, pp. 1602–1610, 1999. View at Google Scholar
  178. S. Nakamura, M. Nagahama, Y. Kagami et al., “Hodgkin's disease expressing follicular dendritic cell marker CD21 without any other B-cell marker: a clinicopathologic study of nine cases,” American Journal of Surgical Pathology, vol. 23, no. 4, pp. 363–376, 1999. View at Publisher · View at Google Scholar
  179. J. Mohan, J. Dement-Brown, S. Maier, T. Ise, B. Kempkes, and M. Tolnay, “Epstein-Barr virus nuclear antigen 2 induces FcRH5 expression through CBF1,” Blood, vol. 107, no. 11, pp. 4433–4439, 2006. View at Publisher · View at Google Scholar · View at Scopus
  180. L. Adorini and G. Penna, “Induction of tolerogenic dendritic cells by vitamin D receptor agonists,” Handbook of Experimental Pharmacology, vol. 188, pp. 251–273, 2009. View at Publisher · View at Google Scholar · View at Scopus
  181. Y. Kang, T. Taldone, C. C. Clement et al., “Design of a fluorescence polarization assay platform for the study of human Hsp70,” Bioorganic and Medicinal Chemistry Letters, vol. 18, no. 13, pp. 3749–3751, 2008. View at Publisher · View at Google Scholar · View at Scopus
  182. X. Ma, H. Zhao, J. Shan et al., “PDCD10 interacts with Ste20-related kinase MST4 to promote cell growth and transformation via modulation of the ERK pathway,” Molecular Biology of the Cell, vol. 18, no. 6, pp. 1965–1978, 2007. View at Publisher · View at Google Scholar · View at Scopus
  183. F. Marchetti and S. Venkatachalam, “The multiple roles of Bub1 in chromosome segregation during mitosis and meiosis,” Cell Cycle, vol. 9, no. 1, pp. 58–63, 2010. View at Google Scholar · View at Scopus
  184. L. Y. Tang, N. Deng, L. S. Wang et al., “Quantitative phosphoproteome profiling of Wnt3a-mediated signaling network: Indicating the involvement of ribonucleoside-diphosphate reductase M2 subunit phosphorylation at residue serine 20 in canonical Wnt signal transduction,” Molecular and Cellular Proteomics, vol. 6, no. 11, pp. 1952–1967, 2007. View at Publisher · View at Google Scholar · View at Scopus
  185. B. Chetaille, F. Bertucci, P. Finetti et al., “Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome,” Blood, vol. 113, no. 12, pp. 2765–2775, 2009. View at Publisher · View at Google Scholar · View at Scopus
  186. V. Brune, E. Tiacci, I. Pfeil et al., “Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis,” Journal of Experimental Medicine, vol. 205, no. 10, pp. 2251–2268, 2008. View at Publisher · View at Google Scholar · View at Scopus
  187. J. Desfrançois, A. Moreau-Aubry, V. Vignard et al., “Double positive CD4CD8 αβ T cells: a new tumor-reactive population in human melanomas,” PLoS ONE, vol. 5, no. 1, article e8437, 2010. View at Publisher · View at Google Scholar · View at Scopus
  188. J. Desfrançois, L. Derré, M. Corvaisier et al., “Increased frequency of nonconventional double positive CD4CD8 αβ T cells in human breast pleural effusions,” International Journal of Cancer, vol. 125, no. 2, pp. 374–380, 2009. View at Publisher · View at Google Scholar
  189. F. A. Zuckermann, “Extrathymic CD4/CD8 double positive T cells,” Veterinary Immunology and Immunopathology, vol. 72, no. 1-2, pp. 55–66, 1999. View at Publisher · View at Google Scholar · View at Scopus
  190. P. Ghia, G. Prato, S. Stella, C. Scielzo, M. Geuna, and F. Caligaris-Cappio, “Age-dependent accumulation of monoclonal CD4CD8 double positive T lymphocytes in the peripheral blood of the elderly,” British Journal of Haematology, vol. 139, no. 5, pp. 780–790, 2007. View at Publisher · View at Google Scholar · View at Scopus
  191. A. M. Carella, P. Carlier, A. Congiu et al., “Nine years' experience with ABMT in 128 patients with Hodgkin's disease: an Italian study group report,” Leukemia, vol. 5, supplement 1, pp. 68–71, 1991. View at Google Scholar
  192. J. H. Mendler and J. W. Friedberg, “Salvage therapy in Hodgkin's lymphoma,” Oncologist, vol. 14, no. 4, pp. 425–432, 2009. View at Publisher · View at Google Scholar · View at Scopus
  193. M. Seftel and M. Rubinger, “The role of hematopoietic stem cell transplantation in advanced Hodgkin Lymphoma,” Transfusion and Apheresis Science, vol. 37, no. 1, pp. 49–56, 2007. View at Publisher · View at Google Scholar · View at Scopus
  194. H. C. Fung, P. Stiff, J. Schriber et al., “Tandem autologous stem cell transplantation for patients with primary refractory or poor risk recurrent Hodgkin lymphoma,” Biology of Blood and Marrow Transplantation, vol. 13, no. 5, pp. 594–600, 2007. View at Publisher · View at Google Scholar · View at Scopus
  195. T. Kewalramani, S. D. Nimer, A. D. Zelenetz et al., “Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma,” Bone Marrow Transplantation, vol. 32, no. 7, pp. 673–679, 2003. View at Publisher · View at Google Scholar · View at Scopus
  196. C. Steidl, T. Lee, S. P. Shah et al., “Tumor-associated macrophages and survival in classic Hodgkin's lymphoma,” New England Journal of Medicine, vol. 362, no. 10, pp. 875–885, 2010. View at Publisher · View at Google Scholar · View at Scopus
  197. V. T. DeVita and J. Costa, “Toward a personalized treatment of Hodgkin's disease,” New England Journal of Medicine, vol. 362, no. 10, pp. 942–943, 2010. View at Publisher · View at Google Scholar · View at Scopus
  198. T. Laitala-Leinonen, “Update on the development of microRNA and siRNA molecules as regulators of cell physiology,” Recent Patents on DNA & Gene Sequences, vol. 4, no. 2, pp. 113–121, 2010. View at Google Scholar
  199. J. Kluiver, S. Poppema, D. de Jong et al., “BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas,” Journal of Pathology, vol. 207, no. 2, pp. 243–249, 2005. View at Publisher · View at Google Scholar · View at Scopus
  200. G. Gatto, A. Rossi, D. Rossi, S. Kroening, S. Bonatti, and M. Mallardo, “Epstein-Barr virus latent membrane protein 1 trans-activates miR-155 transcription through the NF-κB pathway,” Nucleic Acids Research, vol. 36, no. 20, pp. 6608–6619, 2008. View at Publisher · View at Google Scholar
  201. J. H. Gibcus, L. P. Tan, G. Harms et al., “Hodgkin lymphoma cell lines are characterized by a specific miRNA expression profile,” Neoplasia, vol. 11, no. 2, pp. 167–176, 2009. View at Publisher · View at Google Scholar · View at Scopus
  202. A. Navarro, A. Gaya, A. Martinez et al., “MicroRNA expression profiling in classic Hodgkin lymphoma,” Blood, vol. 111, no. 5, pp. 2825–2832, 2008. View at Publisher · View at Google Scholar · View at Scopus
  203. K. Nie, M. Gomez, P. Landgraf et al., “MicroRNA-mediated down-regulation of PRDM1/Blimp-1 in Hodgkin/Reed- Sternberg cells: a potential pathogenetic lesion in Hodgkin lymphomas,” American Journal of Pathology, vol. 173, no. 1, pp. 242–252, 2008. View at Publisher · View at Google Scholar · View at Scopus
  204. A. Navarro, T. Diaz, A. Martinez et al., “Regulation of JAK2 by miR-135a: prognostic impact in classic Hodgkin lymphoma,” Blood, vol. 114, no. 14, pp. 2945–2951, 2009. View at Publisher · View at Google Scholar · View at Scopus
  205. P. van Vlierberghe, A. de Weer, P. Mestdagh et al., “Comparison of miRNA profiles of microdissected Hodgkin/Reed-Sternberg cells and Hodgkin cell lines versus CD77 B-cells reveals a distinct subset of differentially expressed miRNAs,” British Journal of Haematology, vol. 147, no. 5, pp. 686–690, 2009. View at Publisher · View at Google Scholar · View at Scopus
  206. A. Yoshimura, “Regulation of cytokine signaling by the SOCS and Spred family proteins,” Keio Journal of Medicine, vol. 58, no. 2, pp. 73–83, 2009. View at Publisher · View at Google Scholar · View at Scopus
  207. J. L. Buckler, X. Liu, and L. A. Turka, “Regulation of T-cell responses by PTEN,” Immunological Reviews, vol. 224, no. 1, pp. 239–248, 2008. View at Publisher · View at Google Scholar · View at Scopus
  208. A. Nieters, L. Beckmann, E. Deeg, and N. Becker, “Gene polymorphisms in Toll-like receptors, interleukin-10, and interleukin-10 receptor alpha and lymphoma risk,” Genes and Immunity, vol. 7, no. 8, pp. 615–624, 2006. View at Publisher · View at Google Scholar · View at Scopus
  209. S. Hohaus, M. Giachelia, G. Massini et al., “Clinical significance of interleukin-10 gene polymorphisms and plasma levels in Hodgkin lymphoma,” Leukemia Research, vol. 33, no. 10, pp. 1352–1356, 2009. View at Publisher · View at Google Scholar · View at Scopus
  210. E. T. Chang, T. Zheng, E. G. Weir et al., “Aspirin and the risk of Hodgkin's lymphoma in a population-based case-control study,” Journal of the National Cancer Institute, vol. 96, no. 4, pp. 305–315, 2004. View at Google Scholar
  211. Y. Yamamoto, M. J. Yin, K. M. Lin, and R. B. Gaynor, “Sulindac inhibits activation of the NF-κB pathway,” Journal of Biological Chemistry, vol. 274, no. 38, pp. 27307–27314, 1999. View at Publisher · View at Google Scholar · View at Scopus
  212. E. T. Chang, B. M. Birmann, J. L. Kasperzyk et al., “Polymorphic variation in NFKB1 and other aspirin-related genes and risk of Hodgkin lymphoma,” Cancer Epidemiology Biomarkers and Prevention, vol. 18, no. 3, pp. 976–986, 2009. View at Publisher · View at Google Scholar
  213. E. T. Chang, D. P. Cronin-Fenton, S. Friis, H. Hjalgrim, H. T. Sørensen, and L. Pedersen, “Aspirin and other nonsteroidal anti-inflammatory drugs in relation to Hodgkin lymphoma risk in Northern Denmark,” Cancer Epidemiology Biomarkers and Prevention, vol. 19, no. 1, pp. 59–64, 2010. View at Publisher · View at Google Scholar
  214. R. El-Zein, C. M. Monroy, C. J. Etzel et al., “Genetic polymorphisms in DNA repair genes as modulators of Hodgkin disease risk,” Cancer, vol. 115, no. 8, pp. 1651–1659, 2009. View at Publisher · View at Google Scholar · View at Scopus
  215. J. A. Shafer, C. R. Cruz, A. M. Leen et al., “Antigen-specific cytotoxic T lymphocytes can target chemoresistant side-population tumor cells in Hodgkin lymphoma,” Leukemia and Lymphoma, vol. 51, no. 5, pp. 870–880, 2010. View at Publisher · View at Google Scholar · View at Scopus
  216. M. S. Staege, U. Banning-Eichenseer, G. Weißflog et al., “Gene expression profiles of Hodgkin's lymphoma cell lines with different sensitivity to cytotoxic drugs,” Experimental Hematology, vol. 36, no. 7, pp. 886–896, 2008. View at Publisher · View at Google Scholar · View at Scopus
  217. H. Kashkar, A. Deggerich, J. M. Seeger et al., “NF-κB-independent down-regulation of XIAP by bortezomib sensitizes HL B cells against cytotoxic drugs,” Blood, vol. 109, no. 9, pp. 3982–3988, 2007. View at Publisher · View at Google Scholar · View at Scopus
  218. K. V. Foyil and N. L. Bartlett, “Anti-CD30 antibodies for Hodgkin lymphoma,” Current Hematologic Malignancy Reports, vol. 5, no. 3, pp. 140–147, 2010. View at Publisher · View at Google Scholar · View at Scopus
  219. S. Čulić, V. Armanda, D. Kuljis, I. Kuzmic, A. Pranic-Kragic, and S. Jankovic, “Anti-CD20 monoclonal antibody (rituximab) for therapy of cd20-positive nodular lymphocyte-predominant Hodgkin lymphoma in an 10-year-old girl,” Pediatric Hematology and Oncology, vol. 23, no. 8, pp. 661–666, 2006. View at Publisher · View at Google Scholar · View at Scopus
  220. N. Zojer, S. Mirzaei, and H. Ludwig, “Successful treatment of a patient with lymphocyte-predominant Hodgkin's lymphoma with yttrium-90-ibritumomab tiuxetan,” European Journal of Haematology, vol. 81, no. 4, pp. 322–324, 2008. View at Publisher · View at Google Scholar · View at Scopus
  221. H. Schulz, U. Rehwald, F. Morschhauser et al., “Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG),” Blood, vol. 111, no. 1, pp. 109–111, 2008. View at Publisher · View at Google Scholar · View at Scopus
  222. B. C. Ekstrand, J. B. Lucas, S. M. Horwitz et al., “Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial,” Blood, vol. 101, no. 11, pp. 4285–4289, 2003. View at Publisher · View at Google Scholar · View at Scopus
  223. L. Pijuan, L. Vicioso, B. Bellosillo et al., “CD20-negative t-cell-rich b-cell lymphoma as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with rituximabL: a molecular analysis using laser capture microdissection,” American Journal of Surgical Pathology, vol. 29, no. 10, pp. 1399–1403, 2005. View at Publisher · View at Google Scholar · View at Scopus
  224. F. Jundt, O. Acikgöz, S. H. Kwon et al., “Aberrant expression of Notch1 interferes with the B-lymphoid phenotype of neoplastic B cells in classical Hodgkin lymphoma,” Leukemia, vol. 22, no. 8, pp. 1587–1594, 2008. View at Publisher · View at Google Scholar · View at Scopus
  225. M. Vockerodt, S. L. Morgan, M. Kuo et al., “The Epstein-Barr virus oncoprotein, latent membrane protein-1, reprograms germinal centre B cells towards a Hodgkin's Reed-Sternberg-like phenotype,” Journal of Pathology, vol. 216, no. 1, pp. 83–92, 2008. View at Publisher · View at Google Scholar · View at Scopus
  226. I. Schwering, A. Bräuninger, U. Klein et al., “Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma,” Blood, vol. 101, no. 4, pp. 1505–1512, 2003. View at Publisher · View at Google Scholar · View at Scopus
  227. Y. Oki and A. Younes, “Does rituximab have a place in treating classic Hodgkin lymphoma?” Current Hematologic Malignancy Reports, vol. 5, no. 3, pp. 135–139, 2010. View at Publisher · View at Google Scholar · View at Scopus
  228. R. J. Jones, C. D. Gocke, Y. L. Kasamon et al., “Circulating clonotypic B cells in classic Hodgkin lymphoma,” Blood, vol. 113, no. 23, pp. 5920–5926, 2009. View at Publisher · View at Google Scholar · View at Scopus
  229. A. Younes, J. Romaguera, F. Hagemeister et al., “A pilot study of rituximab in patients with recurrent, classic Hodgkin disease,” Cancer, vol. 98, no. 2, pp. 310–314, 2003. View at Publisher · View at Google Scholar · View at Scopus
  230. Y. Oki, B. Pro, L. E. Fayad et al., “Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma,” Cancer, vol. 112, no. 4, pp. 831–836, 2008. View at Publisher · View at Google Scholar · View at Scopus
  231. G. Corazzelli, G. Capobianco, M. Arcamone et al., “Rituximab plus gemcitabine, ifosfamide, oxaliplatin (R-GIFOX) as salvage therapy for recurrent Hodgkin lymphoma,” Journal of Clinical Oncology, vol. 27, article 15s, 2009. View at Google Scholar
  232. A. R. Copeland, Y. Cao, M. Fanale et al., “Final report of a phase-II study of rituximab plus ABVD for patients with newly diagnosed advanced stage classical Hodgkin lymphoma.: results of long follow up and comparison to institutional historical data,” Blood, vol. 114, article 1680, 2009. View at Google Scholar
  233. A. Wedgwood, M. Fanale, and L. Fayad, “Rituximab + ABVD improves event-free survival (EFS) in patients with classical Hodgkin lymphoma in all International Prognostic Score (IPS) groups and in patients who have PET positive disease after 2-3 cycles of therapy,” Blood, vol. 110, article 215, 2008. View at Google Scholar
  234. A. F. Wahl, K. Klussman, J. D. Thompson et al., “The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in Vitro and affects antitumor activity in models of Hodgkin's disease,” Cancer Research, vol. 62, no. 13, pp. 3736–3742, 2002. View at Google Scholar · View at Scopus
  235. C. G. Cerveny, C. L. Law, R. S. McCormick et al., “Signaling via the anti-CD30 mAb SGN-30 sensitizes Hodgkin's disease cells to conventional chemotherapeutics,” Leukemia, vol. 19, no. 9, pp. 1648–1655, 2005. View at Publisher · View at Google Scholar · View at Scopus
  236. E. Oflazoglu, I. J. Stone, K. A. Gordon et al., “Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30,” Blood, vol. 110, no. 13, pp. 4370–4372, 2007. View at Publisher · View at Google Scholar · View at Scopus
  237. A. Forero-Torres, J. P. Leonard, A. Younes et al., “A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma,” British Journal of Haematology, vol. 146, no. 2, pp. 171–179, 2009. View at Publisher · View at Google Scholar · View at Scopus
  238. X. F. Hu and P. X. Xing, “MDX-060 medarex,” Current Opinion in Investigational Drugs, vol. 6, no. 12, pp. 1266–1271, 2005. View at Google Scholar · View at Scopus
  239. S. M. Ansell, S. M. Horwitz, A. Engert et al., “Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma,” Journal of Clinical Oncology, vol. 25, no. 19, pp. 2764–2769, 2007. View at Publisher · View at Google Scholar · View at Scopus
  240. J. A. Francisco, C. G. Cerveny, D. L. Meyer et al., “cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity,” Blood, vol. 102, no. 4, pp. 1458–1465, 2003. View at Publisher · View at Google Scholar · View at Scopus
  241. A. Younes, A. Forero-Torres, N. L. Bartlett et al., “Objective responses in a phase I dose-escalation study of SGN-35, a novel antibody-drug conjugate (ADC) targeting CD30, in patients with relapsed or refractory Hodgkin lymphoma,” in Proceedings of Annual Meeting American Society of Clinical Oncology (ASCO '08), 2008.
  242. A. Younes, A. Forero-Torres, N. L. Bartlett et al., “Multiple complete responses in a phase 1 dose-escalation study of the antibody-drug conjugate SGN-35 in patients with relapsed or refractory CD30-positive lymphomas,” in Proceedings of the 50th ASH Annual Meeting, San Frncisco, Calif, USA, 2008.
  243. N. M. Okeley, J. B. Miyamoto, X. Zhang et al., “Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate,” Clinical Cancer Research, vol. 16, no. 3, pp. 888–897, 2010. View at Publisher · View at Google Scholar · View at Scopus
  244. T. W. Dennie and J. M. Kolesar, “Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma,” Clinical Therapeutics, vol. 31, no. 2, pp. 2290–2311, 2009. View at Publisher · View at Google Scholar · View at Scopus
  245. B. D. Cheson and M. J. Rummel, “Bendamustine: rebirth of an old drug,” Journal of Clinical Oncology, vol. 27, no. 9, pp. 1492–1501, 2009. View at Publisher · View at Google Scholar · View at Scopus
  246. J. W. Friedberg, P. Cohen, L. Chen et al., “Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study,” Journal of Clinical Oncology, vol. 26, no. 2, pp. 204–210, 2008. View at Publisher · View at Google Scholar · View at Scopus
  247. A. J. Moskowitz, P. A. Hamlin Jr., J. Gerecitano et al., “Bendamustine is highly active in heavily pre-treated relapsed and refractory Hodgkin Lymphoma and serves as a bridge to allogeneic stem cell transplant,” in Proceedings of ASH Annual Meeting Abstracts, vol. 114, p. 720, 2009.
  248. T. A. Fehniger, S. Larson, K. Trinkaus et al., “A phase II multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma,” in Proceedings of ASH Annual Meeting Abstracts, vol. 114, p. 3693, 2009.
  249. B. Böll, P. Borchmann, M. S. Topp et al., “Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma,” British Journal of Haematology, vol. 148, no. 3, pp. 480–482, 2010. View at Publisher · View at Google Scholar · View at Scopus
  250. M. A. Weniger, T. F. E. Barth, and P. Möller, “Genomic alterations in Hodgkin's lymphoma,” International Journal of Hematology, vol. 83, no. 5, pp. 379–384, 2006. View at Publisher · View at Google Scholar · View at Scopus
  251. D. Buglio, V. Mamidipudi, N. M. Khaskhely et al., “The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism,” British Journal of Haematology, vol. 151, no. 4, pp. 387–396, 2010. View at Publisher · View at Google Scholar
  252. I. Hartlapp, C. Pallasch, G. Weibert, A. Kemkers, M. Hummel, and D. Re, “Depsipeptide induces cell death in Hodgkin lymphoma-derived cell lines,” Leukemia Research, vol. 33, no. 7, pp. 929–936, 2009. View at Publisher · View at Google Scholar · View at Scopus
  253. A. Gloghini, D. Buglio, N. M. Khaskhely et al., “Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors,” British Journal of Haematology, vol. 147, no. 4, pp. 515–525, 2009. View at Publisher · View at Google Scholar · View at Scopus
  254. D. Buglio, G. V. Georgakis, S. Hanabuchi et al., “Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines,” Blood, vol. 112, no. 4, pp. 1424–1433, 2008. View at Publisher · View at Google Scholar · View at Scopus
  255. H. Adams, F. R. Fritzsche, S. Dirnhofer, G. Kristiansen, and A. Tzankov, “Class i histone deacetylases 1, 2 and 3 are highly expressed in classical Hodgkin's lymphoma,” Expert Opinion on Therapeutic Targets, vol. 14, no. 6, pp. 577–584, 2010. View at Publisher · View at Google Scholar · View at Scopus
  256. A. Younes, B. Pro, M. Fanale et al., “Isotype-selective HDAC inhibitor MGCD0103 decreases serum TARC concentrations and produces clinical responses in heavily pretreated patients with relapsed classical Hodgkin lymphoma (HL),” in Proceedings of the ASH Annual Meeting Abstracts, vol. 110, p. 2566, 2007.
  257. M. Zhou, F. M. Fadlelmola, J. B. Cohn, B. Skinnider, R. D. Gascoyne, and D. Banerjee, “Constitutive overexpression of a novel 21 kDa protein by Hodgkin lymphoma and aggressive non-Hodgkin lymphomas,” Molecular Cancer, vol. 7, article 12, 2008. View at Publisher · View at Google Scholar · View at Scopus
  258. D. Murphy, J. Parker, M. Zhou et al., “Constitutively overexpressed 21 kDa protein in Hodgkin lymphoma and aggressive non-Hodgkin lymphomas identified as cytochrome B(CYB5B),” Molecular Cancer, vol. 9, article 14, 2010. View at Publisher · View at Google Scholar · View at Scopus